Anti-Diabetes Drugs - North America

In North America, the revenue in the Anti-Diabetes Drugs market is anticipated to reach US$40.06bn by 2024.
It is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 6.88%, leading to a market volume of US$55.87bn by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$37.84bn in 2024.
In North America, the demand for innovative anti-diabetes drugs is on the rise, driven by the increasing prevalence of diabetes and a growing aging population.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in North America is witnessing a steady growth owing to the rise in the number of people suffering from diabetes.

Customer preferences: The customers in North America are increasingly opting for anti-diabetes drugs due to the high prevalence of diabetes in the region. The preference for oral anti-diabetic drugs is increasing as they are more convenient to use and have fewer side effects as compared to other forms of treatment.

Trends in the market: The market for anti-diabetes drugs in North America is witnessing a shift towards combination therapies. Combination therapies are becoming increasingly popular as they offer better glycemic control and reduce the risk of side effects. The use of biosimilars is also on the rise due to their cost-effectiveness. The market is also witnessing an increase in the development of drugs that target specific pathways in the treatment of diabetes.

Local special circumstances: The high prevalence of diabetes in North America is one of the major factors driving the growth of the anti-diabetes drugs market in the region. The sedentary lifestyle, unhealthy dietary habits, and increasing obesity rates are contributing to the rise in the number of people suffering from diabetes. The aging population is also a major factor as diabetes is more common among the elderly.

Underlying macroeconomic factors: The healthcare expenditure in North America is among the highest in the world. The high healthcare expenditure is leading to increased investment in research and development of new drugs. The favorable regulatory environment is also contributing to the growth of the anti-diabetes drugs market in the region. The increasing demand for anti-diabetes drugs is leading to the entry of new players in the market, which is intensifying the competition.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.